PlainRecalls
FDA Drug Low Class III Completed

Nexlizet (bempedoic acid and ezetimibe), 180ng/18mg, 30 tablets, Rx only, Manufactured for: Esperion Therapeutics, Inc, Ann Arbor, MI 48108, NDC 72426-818-03

Reported: September 13, 2023 Initiated: August 16, 2023 #D-1143-2023

Product Description

Nexlizet (bempedoic acid and ezetimibe), 180ng/18mg, 30 tablets, Rx only, Manufactured for: Esperion Therapeutics, Inc, Ann Arbor, MI 48108, NDC 72426-818-03

Reason for Recall

Failed dissolution specifications: below specification results at stability 12-month

Details

Recalling Firm
Esperion
Units Affected
45,240 bottles
Distribution
Nationwide USA
Location
Ann Arbor, MI

Frequently Asked Questions

What product was recalled?
Nexlizet (bempedoic acid and ezetimibe), 180ng/18mg, 30 tablets, Rx only, Manufactured for: Esperion Therapeutics, Inc, Ann Arbor, MI 48108, NDC 72426-818-03. Recalled by Esperion. Units affected: 45,240 bottles.
Why was this product recalled?
Failed dissolution specifications: below specification results at stability 12-month
Which agency issued this recall?
This recall was issued by the FDA Drug on September 13, 2023. Severity: Low. Recall number: D-1143-2023.